

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update

<https://marketpublishers.com/r/C8FD87103D6EN.html>

Date: February 2016

Pages: 46

Price: US\$ 440.00 (Single User License)

ID: C8FD87103D6EN

Abstracts

Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update

The Competitive Intelligence Report Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update“ provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) or its receptors (VEGF-R) for treatment of a variety of cancer indications and retinal diseases as of February 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Therapeutic antibodies targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGF-R) are a highly successful class of products as evidenced by total sales of US\$ 15 bln in 2015. While Avastin has been known for years as a blockbuster biologic, anti-VEGF products Lucentis and Eylea for treatment of retinal diseases posted for the first time in 2015 higher sales than the anti-VEGF/R products for cancer treatment.

The commercial success of Avastin as a single product approved for many cancer indications and the forthcoming patent expiries in the major markets have attracted a number of biosimilar developments in advanced clinical stages.

Until now, less attention has been paid to anti-VEGF antibodies used for treatment of ophthalmic diseases although the approved antibody products are attractive targets for

the second wave of biosimilar antibodies because of the impressive market growth fueled by the clinical success and patent expiries in the mid-term.

The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies or proteins for treatment of cancer and neo-angiogenic eye diseases. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Contents

1) Marketed Anti-VEGF/R Products in Oncology

Avastin, Zaltrap & Cyramza Sales 2008 – 2015

Avastin Sales and Indication Portfolio

Zaltrap Sales and Indication Portfolio

Cyramza Sales and Indication Portfolio

2) Anti-VEGF Biosuperiors of Avastin and Zaltrap

Anti-VEGF Biosuperior Pipeline in Oncology

Bispecific Anti-VEGF Pipeline in Oncology

3) Anti-VEGF-R Biosuperiors of Cyramza

Anti-VEGF-R Biosuperior Pipeline in Oncology

Bispecific Anti-VEGF-R Pipeline in Oncology

4) Avastin Biosimilar Pipeline in Oncology

5) Marketed Anti-VEGF Products in Ophthalmology

Lucentis & Eylea Sales 2008 – 2015

Lucentis Sales & Indication Portfolio

Eylea Sales & Indication Portfolio

6) Anti-VEGF Biosuperiors of Lucentis and Eylea

Biosuperior Anti-VEGF in Ophthalmology

Biosuperior Bispecific Anti-VEGF and Anti-VEGF Combinations in Ophthalmology

7) Other Anti-VEGF Molecules in Ophthalmology

8) Lucentis Biosimilars in Ophthalmology

9) Eylea Biosimilars in Ophthalmology

10) Off-Label Use of Anti-VEGF in Ophthalmology

I would like to order

Product name: Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis – a 2016 Update

Product link: <https://marketpublishers.com/r/C8FD87103D6EN.html>

Price: US\$ 440.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C8FD87103D6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

